Recent Updates
Recently added Catalysts
ONC Positive Sentiment

شركة BeOne Medicines تعلن عن إبرام اتفاقية طوعية مع الحكومة الأمريكية لتعزيز وتوسيع إمكانية الحصول على علاجات السرطان المُبتكرة

Key Takeaway: BeOne Medicines has announced a strategic partnership with the U.S. government to enhance access to innovative cancer therapies for American patients. This agreement aims to broaden the availability of these treatments and strengthen the company's presence in the U.S. market. The collaboration reflects BeOne's commitment to improving patient access to advanced oncology solutions.

Market Sentiment Analysis

POSITIVE FACTORS

  • BeOne Medicines expands access to cancer treatments.
  • Partnership with U.S. government enhances drug availability.
  • Strategic agreement aligns with BeOne's mission.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
3.8%
average across 5 past catalysts
Lead asset
Tislelizumab
Phase 3 · Non-small Cell Lung Cancer

Full Press Release Details

SAN CARLOS, Calif.--(BUSINESS WIRE)--$ONC#BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley Annual Global Healthcare Conference on September 14, 2026, with a fireside chat at 11:30 a.m. EDT.
The live webcast of this event can be accessed from the investors section of the Company’s website athttps://ir.beonemedicines.com. An archived webcast will be available on the Company’s website.

About BeOne Medicines

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.
To learn more about BeOne, please visitwww.beonemedicines.comand follow us onLinkedIn,X,FacebookandInstagram.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne’s plans, commitments, aspirations and goals related to BeOne’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in BeOne’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”) as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the SEC. All information in this press release is as of the date hereof, and BeOne undertakes no duty to update such information unless required by law.

Investor Contact:Liza HeapesTel:+1 857-302-5663ir@beonemed.comMedia Contact:Kyle BlankenshipTel:+1 667-351-5176media@beonemed.com

Frequently Asked Questions

What is the purpose of BeOne Medicines' new partnership?

The partnership aims to enhance access to innovative cancer therapies for American patients.

How will this agreement benefit cancer patients?

It will broaden the availability of advanced cancer treatments in the U.S. market.

What is BeOne Medicines' focus area?

BeOne Medicines specializes in oncology and cancer treatment solutions.

What does this partnership signify for BeOne Medicines?

It reflects BeOne's commitment to improving patient access to cancer therapies.

Last updated: Sep 1, 2026